{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:45:34Z","timestamp":1761806734846},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1016\/s0022-510x(99)00304-4","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T15:23:28Z","timestamp":1027610608000},"page":"73-77","source":"Crossref","is-referenced-by-count":28,"title":["The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis"],"prefix":"10.1016","volume":"173","author":[{"given":"B","family":"Sharrack","sequence":"first","affiliation":[]},{"given":"R.A.C","family":"Hughes","sequence":"additional","affiliation":[]},{"given":"R.W","family":"Morris","sequence":"additional","affiliation":[]},{"given":"S","family":"Soudain","sequence":"additional","affiliation":[]},{"given":"O","family":"Wade-Jones","sequence":"additional","affiliation":[]},{"given":"D","family":"Barnes","sequence":"additional","affiliation":[]},{"given":"P","family":"Brown","sequence":"additional","affiliation":[]},{"given":"T","family":"Britton","sequence":"additional","affiliation":[]},{"given":"D.A","family":"Francis","sequence":"additional","affiliation":[]},{"given":"G.D","family":"Perkin","sequence":"additional","affiliation":[]},{"given":"P","family":"Rudge","sequence":"additional","affiliation":[]},{"given":"M","family":"Swash","sequence":"additional","affiliation":[]},{"given":"H.A","family":"Katifi","sequence":"additional","affiliation":[]},{"given":"S","family":"Farmer","sequence":"additional","affiliation":[]},{"given":"J.P","family":"Frankel","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0022-510X(99)00304-4_BIB1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/brain\/114.2.1045","article-title":"The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Brain"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow up","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB6","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1996","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.1987.00520200007008","article-title":"Steroid therapy in multiple sclerosis. Point of view","volume":"44","author":"Troiano","year":"1987","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0140-6736(61)91030-3","article-title":"Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH)","volume":"II","author":"Miller","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.20.5_Part_2.1","article-title":"Co-operative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo \u2014 final report","volume":"20","author":"Rose","year":"1970","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/WNL.36.2.238","article-title":"High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical\u2013immunologic correlations","volume":"36","author":"Durelli","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","article-title":"A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects","volume":"50","author":"Milligan","year":"1987","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jnnp.48.2.157","article-title":"Intravenous methylprednisolone for multiple sclerosis in relapse","volume":"48","author":"Barnes","year":"1985","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","article-title":"Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose","volume":"56","author":"Alam","year":"1993","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.44.1.1","article-title":"Megadose corticosteroids in multiple sclerosis","volume":"44","author":"Kupersmith","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB16","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis","volume":"329","author":"Beck","year":"1993","journal-title":"New Engl. J. Med."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archopht.1995.01100020014004","article-title":"The optic neuritis treatment trial: three-year follow-up results","volume":"113","author":"Beck","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archneur.1985.04060070098026","article-title":"Optic neuritis or multiple sclerosis","volume":"42","author":"Kurtzke","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archneur.1985.04060070096025","article-title":"Optic neuritis and multiple sclerosis","volume":"42","author":"Ebers","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/S0022-510X(99)00304-4_BIB22","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1212\/WNL.44.12.2289","article-title":"A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease","volume":"44","author":"Reder","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/WNL.45.7.1245","article-title":"Copolymer 1: a most reasonable alternative therapy for early relapsing\u2013remitting multiple sclerosis with mild disability","volume":"45","author":"Wolinsky","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/S0022-510X(99)00304-4_BIB24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing\u2013remitting multiple sclerosis","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X99003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X99003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T07:51:03Z","timestamp":1556351463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X99003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["S0022510X99003044"],"URL":"https:\/\/doi.org\/10.1016\/s0022-510x(99)00304-4","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}